New stock news | Yino Weiyi Pharmaceutical, Hong Kong IPO prospectus invalid

Immvira Bioscience Inc. (referred to as Yino Micro Medicine) submitted its Hong Kong IPO prospectus on January 14, 2026, which expired after 6 months on July 14, 2026. Citigroup and CICC acted as its joint sponsors. According to the previous prospectus, Yino Micro Medicine is a biotechnology company focused on clinically driven biological technologies, dedicated to discovering, developing, producing, and commercializing novel oncolytic immunotherapy and engineered exosome therapy. The company has established a product pipeline, including: (i) two oncolytic immunotherapy products for solid tumors, and (ii) five engineered exosome products with clinical application prospects or direct commercialization potential. The company's core product MVR-T3011 is a Phase II oncolytic immunotherapy product targeting herpes simplex virus type 1 (HSV-1), combining potent tumor lysing activity with the expression of anti-PD-1 antibodies and IL-12. MVR-T3011 is currently being evaluated as part of mono or combination therapy, covering a spectrum of indications including bladder cancer (including second-line treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) after BCG treatment, first-line treatment for NMIBC, and neoadjuvant or adjuvant therapy for muscle-invasive bladder cancer (MIBC)), third-line treatment for head and neck squamous cell carcinoma (HNSCC), and other solid tumor indications.